best glp 1 for cholesterol Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis GLP-1 Drugs for People With

FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available

Both Novo Nordisk and Eli Lilly are developing oral pill versions that should make treatment more convenient and potentially expand adoption

Researchers in an international collaboration across the University of Ottawa Eye Institute, University of Toronto, McMaster University, and Doheny Eye Institute UCLA conducted one of the largest global studies on the topic to date

That is the gap IV delivery closes